Nicola Potter

ORCID

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 19

Top Venues

Blood

Leukemia

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Blood advances

This page only lists publications with an associated author ORCID identifier.

Publications

Stuart Scott, Alison Devonshire, Richard Dilon, Christian Thiede, Nicholas C P Cross, Helen E White, Leandro Lo Cascio, Katya Mokretar, Nicola Potter, Christopher S Hourigan, Jerald P Radich, Adam Corner, Véronique Laloux, Gemma Halliday, Daniel Dilks, Tom Morrison, Katelyn Gilmour, Ashley Cartwright, Liam Whitby
Recommendations from the AML molecular MRD expert advisory board. Leukemia 38 (7) (2024)
Jad Othman, Nicola Potter, Adam Ivey, Jelena Jovanovic, Manohursingh Runglall, Sylvie D Freeman, Amanda Frances Gilkes, Ian Thomas, Sean J Johnson, Joanna Canham, James Durrell Cavenagh, Panagiotis Kottaridis, Claire Arnold, Hans Beier Ommen, Ulrik Malthe Overgaard, Mike Dennis, Alan K Burnett, Charlotte S Wilhelm-Benartzi, Richard Dilon, Nigel H Russell
Post induction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood (2024)
Stuart Scott, Alison Devonshire, Richard Dilon, Christian Thiede, Nicholas C P Cross, Helen E White, Leandro Lo Cascio, Katya Mokretar, Nicola Potter, Christopher S Hourigan, Jerald P Radich, Adam Corner, Véronique Laloux, Gemma Halliday, Daniel Dilks, Tom Morrison, Katelyn Gilmour, Ashley Cartwright, Liam Whitby
Recommendations from the AML molecular MRD expert advisory board. Leukemia (2024)
Jad Othman, Nicola Potter, Adam Ivey, Yanis Tazi, Elli Papaemmanuil, Jelena Jovanovic, Sylvie D Freeman, Amanda Frances Gilkes, Rosemary E Gale, Tanya Rapoz-D'Silva, Manohursingh Runglall, Michelle Kleeman, Pawan Dhami, Ian Thomas, Sean J Johnson, Joanna Canham, James Durrell Cavenagh, Panagiotis Kottaridis, Claire Arnold, Hans Beier Ommen, Ulrik Malthe Overgaard, Mike Dennis, Alan Kenneth Burnett, Charlotte S Wilhelm-Benartzi, Brian James Patrick Huntly, Nigel H Russell, Richard James Dillon
Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML. Blood (2024)
Jad Othman, Nicola Potter, Adam Ivey, Jelena Jovanovic, Manohursingh Runglall, Sylvie D Freeman, Amanda Gilkes, Ian Thomas, Sean J Johnson, Joanna Canham, Jamie Cavenagh, Panagiotis Kottaridis, Claire Arnold, Hans Beier Ommen, Ulrik Malthe Overgaard, Mike Dennis, Alan Burnett, Charlotte Wilhelm-Benartzi, Richard Dilon, Nigel H Russell
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood 143 (19) (2024)
Nigel H Russell, Charlotte Wilhelm-Benartzi, Jad Othman, Richard Dilon, Stephen Knapper, Leona M Batten, Joanna Canham, Emily L Hinson, Sophie Betteridge, Ulrik Malthe Overgaard, Amanda Gilkes, Nicola Potter, Priyanka Mehta, Panagiotis Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Sylvie D Freeman, Mike Dennis, null null
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Stuart Scott, Alison Devonshire, Richard Dilon, Christian Thiede, Nicholas C P Cross, Helen E White, Leandro Lo Cascio, Katya Mokretar, Nicola Potter, Christopher S Hourigan, Jerald P Radich, Adam Corner, Véronique Laloux, Gemma Halliday, Daniel Dilks, Tom Morrison, Katelyn Gilmour, Ashley Cartwright, Liam Whitby
Recommendations from the AML molecular MRD expert advisory board. Leukemia 38 (7) (2024)
Jad Othman, Nicola Potter, Adam Ivey, Jelena Jovanovic, Manohursingh Runglall, Sylvie D Freeman, Amanda Gilkes, Ian Thomas, Sean J Johnson, Joanna Canham, Jamie Cavenagh, Panagiotis Kottaridis, Claire Arnold, Hans Beier Ommen, Ulrik Malthe Overgaard, Mike Dennis, Alan Burnett, Charlotte Wilhelm-Benartzi, Richard Dilon, Nigel H Russell
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood 143 (19) (2024)
Jad Othman, Nicola Potter, Adam Ivey, Jelena Jovanovic, Manohursingh Runglall, Sylvie D Freeman, Amanda Gilkes, Ian Thomas, Sean J Johnson, Joanna Canham, Jamie Cavenagh, Panagiotis Kottaridis, Claire Arnold, Hans Beier Ommen, Ulrik Malthe Overgaard, Mike Dennis, Alan Burnett, Charlotte Wilhelm-Benartzi, Richard Dilon, Nigel H Russell
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood 143 (19) (2024)
Jad Othman, Nicola Potter, Adam Ivey, Yanis Tazi, Elli Papaemmanuil, Jelena Jovanovic, Sylvie D Freeman, Amanda Gilkes, Rosemary E Gale, Tanya Rapoz-D'Silva, Manohursingh Runglall, Michelle Kleeman, Pawan Dhami, Ian Thomas, Sean J Johnson, Joanna Canham, Jamie Cavenagh, Panagiotis Kottaridis, Claire Arnold, Hans Beier Ommen, Ulrik Malthe Overgaard, Mike Dennis, Alan Burnett, Charlotte Wilhelm-Benartzi, Brian James Patrick Huntly, Nigel H Russell, Richard Dillon
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML. Blood 144 (7) (2024)
Stuart Scott, Alison Devonshire, Richard Dilon, Christian Thiede, Nicholas C P Cross, Helen E White, Leandro Lo Cascio, Katya Mokretar, Nicola Potter, Christopher S Hourigan, Jerald P Radich, Adam Corner, Véronique Laloux, Gemma Halliday, Daniel Dilks, Tom Morrison, Katelyn Gilmour, Ashley Cartwright, Liam Whitby
Recommendations from the AML molecular MRD expert advisory board. Leukemia 38 (7) (2024)
Nigel H Russell, Charlotte Wilhelm-Benartzi, Jad Othman, Richard Dilon, Stephen Knapper, Leona M Batten, Joanna Canham, Emily L Hinson, Sophie Betteridge, Ulrik Malthe Overgaard, Amanda Gilkes, Nicola Potter, Priyanka Mehta, Panagiotis Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Sylvie D Freeman, Mike Dennis, null null
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Liesbeth Vanheeswijck, Sanjay Tewari, Robin Dowse, Nicola Potter, Jelena Jovanovic, Caroline L Furness, Elsje Van Rijswijk
Pitfalls in Diagnosis: JMML versus KMT2A Rearranged Juvenile AML. Case reports in hematology 2024 (2024)
Nigel H Russell, Charlotte Wilhelm-Benartzi, Jad Othman, Richard Dilon, Stephen Knapper, Leona M Batten, Joanna Canham, Emily L Hinson, Sophie Betteridge, Ulrik Malthe Overgaard, Amanda Gilkes, Nicola Potter, Priyanka Mehta, Panagiotis Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Sylvie D Freeman, Mike Dennis, null null
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (10) (2024)
Jad Othman, Nicola Potter, Adam Ivey, Jelena Jovanovic, Manohursingh Runglall, Sylvie D Freeman, Amanda Frances Gilkes, Ian Thomas, Sean J Johnson, Joanna Canham, James Durrell Cavenagh, Panagiotis Kottaridis, Claire Arnold, Hans Beier Ommen, Ulrik Malthe Overgaard, Mike Dennis, Alan K Burnett, Charlotte S Wilhelm-Benartzi, Richard Dilon, Nigel H Russell
Post induction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood (2024)
Stuart Scott, Alison Devonshire, Richard Dilon, Christian Thiede, Nicholas C P Cross, Helen E White, Leandro Lo Cascio, Katya Mokretar, Nicola Potter, Christopher S Hourigan, Jerald P Radich, Adam Corner, Véronique Laloux, Gemma Halliday, Daniel Dilks, Tom Morrison, Katelyn Gilmour, Ashley Cartwright, Liam Whitby
Recommendations from the AML molecular MRD expert advisory board. Leukemia 38 (7) (2024)
Nigel H Russell, Charlotte Wilhelm-Benartzi, Jad Othman, Richard Dilon, Stephen Knapper, Leona M Batten, Joanna Canham, Emily L Hinson, Sophie Betteridge, Ulrik Malthe Overgaard, Amanda Gilkes, Nicola Potter, Priyanka Mehta, Panagiotis Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Sylvie D Freeman, Mike Dennis, null null
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (10) (2024)
Carlos Jimenez Chillon, Jad Othman, David Taussig, Carlos Jiménez-Vicente, Alexandra Martínez-Roca, Ing Soo Tiong, Manish Jain, James Aries, Seda Cakmak, Stephen Knapper, Daniel Tuyet Kristensen, Vidhya Murthy, Zacharoula Galani, Charlotte Kallmeyer, Loretta Ngu, David Veale, Simon Bolam, Nina Orfali, Anne Parker, Cara Manson, Jane Parker, Thomas Erblich, Deborah Susan Richardson, Katya Mokretar, Nicola Potter, Ulrik Malthe Overgaard, Anne Stidsholt Roug, Andrew H Wei, Jordi Esteve, Martin Jädersten, Nigel H Russell, Richard Dilon
Venetoclax-based low intensity therapy in molecular failure of NPM1 mutated AML. Blood advances (2023)
Jad Othman, Ing Soo Tiong, Jenny O'Nions, Mike Dennis, Katya Mokretar, Adam Ivey, Michael James Austin, Annie-Louise Latif, Mariam Amer, Wei Yee Chan, Charles R Crawley, Francesca Crolla, Joe Wilson Cross, Raymond Dang, Johnathon Elliot, Chun Yew Fong, Sofia Galli, Paolo Gallipoli, Francesca Hogan, Pallavi Kalkur, Anjum Bashir Khan, Pramila Krishnamurthy, John Laurie, Sun Loo, Scott Marshall, Priyanka Mehta, Vidhya Murthy, Sateesh K Nagumantry, Srinivas Pillai, Nicola Potter, Rob S Sellar, Thomas Taylor, Rui Zhao, Nigel H Russell, Andrew H Wei, Richard Dilon
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based non-intensive therapy. Blood (2023)

Nicola Potter.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Nicola Potter